
Biotech investors, once the envy of Wall Street, have slipped into despondency.
After a double-digit decline in 2021, the sector has fallen another 20% in the new year, erasing billions in value and leading even the most seasoned investors to question whether biotech has further to fall.
Create a display name to comment
This name will appear with your comment